The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 20, 2010
Filed:
Jun. 02, 2005
Bruce D Cohen, East Lyme, CT (US);
Jean Beebe, Salem, CT (US);
Penelope E Miller, Mystic, CT (US);
James D Moyer, East Lyme, CT (US);
Jose R Corvalan, Foster City, CA (US);
Michael Gallo, North Vancouver, CA;
Bruce D Cohen, East Lyme, CT (US);
Jean Beebe, Salem, CT (US);
Penelope E Miller, Mystic, CT (US);
James D Moyer, East Lyme, CT (US);
Jose R Corvalan, Foster City, CA (US);
Michael Gallo, North Vancouver, CA;
Amgen Fremont, Fremont, CA (US);
Pfizer, Inc., New York, NY (US);
Abstract
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies. The invention also relates to gene therapy methods and transgenic animals comprising nucleic acid molecules of the present invention.